News

VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy in patients with type 1 Gaucher disease. The company hopes to increase the production capacity

Arcalyst is used to treat Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). The sBLA submission for Arcalyst is backed by positive

EpiCor is a natural product that helps in the maintenance of the immune system. The clinical studies have demonstrated EpiCor’s immune-balancing properties in helping the body boost or

pSivida is independently developing a product to treat uveitis affecting the posterior segment of the eye (posterior uveitis). In addition, the company has partnered with Pfizer for the

Vascazen is used to treat patients with Omega-3 fatty acids deficiency. Pivotal Therapeutics president Rachelle MacSweeney said the launch of Vascazen in North America is a key milestone

As per the agreement, Altacor will undertake research and development on Proximagen’s 5HT2c programme drug candidate – PRX00933 – in treating glaucoma. The company claims, PRX00933 which is

As per the agreement, UCB has acquired Lectus drug discovery and development programmes targeting ion channels used to treat specific set of Central Nervous System (CNS) indications. UCB

The double-blind, placebo-controlled trial, enrolling 60 US subjects, is designed to assess the pharmacokinetic, pharmacodynamic and safety profile of single escalating doses of CR845 in enteric-coated capsules. Cara

The acquisition is expected to help Tjoapack in its growth strategy. Tjoapack specializes in packaging medicines in a solid dosage form and is known for mass serialisation. By